SURMODICS INC (SRDX) Stock Price, Forecast & Analysis
USA - NASDAQ:SRDX - US8688731004 - Common Stock
SRDX Key Statistics, Chart & Performance
The current stock price of SRDX is 42.98 USD. In the past month the price increased by 52.95%. In the past year, price increased by 9.28%.
SRDX Latest News, Press Relases and Analysis
SRDX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.67 | 222.97B | ||
| ISRG | INTUITIVE SURGICAL INC | 65.23 | 201.33B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.84 | 143.55B | ||
| SYK | STRYKER CORP | 27.96 | 140.79B | ||
| IDXX | IDEXX LABORATORIES INC | 57.57 | 58.07B | ||
| BDX | BECTON DICKINSON AND CO | 13.36 | 55.24B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.12 | 49.98B | ||
| RMD | RESMED INC | 25.33 | 36.59B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.66 | 34.90B | ||
| DXCM | DEXCOM INC | 32.38 | 23.62B | ||
| PODD | INSULET CORP | 72.47 | 23.31B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.39 | 18.26B |
Related stock screener links
About SRDX
Company Profile
Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. The company is headquartered in Eden Prairie, Minnesota and currently employs 389 full-time employees. The company also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the demanding requirements. Its segments include Medical Device and IVD. Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral and coronary. IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.
Company Info
SURMODICS INC
9924 W 74th St
Eden Prairie MINNESOTA 55344 US
CEO: Gary R. Maharaj
Employees: 389
Phone: 19525007000
SURMODICS INC / SRDX FAQ
What does SRDX do?
Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. The company is headquartered in Eden Prairie, Minnesota and currently employs 389 full-time employees. The company also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the demanding requirements. Its segments include Medical Device and IVD. Medical Device segment manufactures and licenses performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that include neurovascular, peripheral and coronary. IVD segment manufactures chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets.
Can you provide the latest stock price for SURMODICS INC?
The current stock price of SRDX is 42.98 USD. The price increased by 0.35% in the last trading session.
Does SURMODICS INC pay dividends?
SRDX does not pay a dividend.
What is the ChartMill technical and fundamental rating of SRDX stock?
SRDX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting SRDX stock to perform?
7 analysts have analysed SRDX and the average price target is 43.86 USD. This implies a price increase of 2.05% is expected in the next year compared to the current price of 42.98.
Can you provide the PE ratio for SRDX stock?
SURMODICS INC (SRDX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.24).
Can you provide the market cap for SURMODICS INC?
SURMODICS INC (SRDX) has a market capitalization of 614.61M USD. This makes SRDX a Small Cap stock.
SRDX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to SRDX. When comparing the yearly performance of all stocks, SRDX is one of the better performing stocks in the market, outperforming 81.83% of all stocks.
SRDX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SRDX. While SRDX seems to be doing ok healthwise, there are quite some concerns on its profitability.
SRDX Financial Highlights
Over the last trailing twelve months SRDX reported a non-GAAP Earnings per Share(EPS) of -0.24. The EPS decreased by -172.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10.38% | ||
| ROE | -15.84% | ||
| Debt/Equity | 0.27 |
SRDX Forecast & Estimates
7 analysts have analysed SRDX and the average price target is 43.86 USD. This implies a price increase of 2.05% is expected in the next year compared to the current price of 42.98.
For the next year, analysts expect an EPS growth of 10.36% and a revenue growth -4.48% for SRDX